KPTI — Karyopharm Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $107.51m
- $343.00m
- $146.07m
Annual income statement for Karyopharm Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 210 | 157 | 146 | 145 | 146 |
| Cost of Revenue | |||||
| Gross Profit | 206 | 152 | 141 | 139 | 140 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 308 | 299 | 276 | 220 | 299 |
| Operating Profit | -98.3 | -142 | -130 | -74.7 | -153 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -124 | -165 | -143 | -76.4 | -196 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -124 | -165 | -143 | -76.4 | -196 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -124 | -165 | -143 | -76.4 | -196 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -124 | -165 | -143 | -76.4 | -196 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -24.7 | -30.3 | -18.8 | -13 | -14.2 |